Board of Directors
Chairman and Chief Executive Officer
William K. Bowes Jr.
Chairman, Nominating & Governance Committee
Charles J. Fisher M.D.
Director
Peter Barton Hutt
Director
Patrick J. Scannon M.D., Ph.D.
Company Founder, Executive Vice President and Chief Biotechnology Officer
W. Denman Van Ness
Lead Independent Director and Chairman, Compensation Committee
Patrick J. Zenner
Director
Steven B. Engle
is XOMA's Chairman and Chief Executive Officer. He has more than 25 years of executive leadership and biotechnology and pharmaceutical industry experience. Prior to joining XOMA in 2007, he served as chairman of the board and chief executive officer of La Jolla Pharmaceutical Company, a publicly held biopharmaceutical company focused on the research and development of therapeutic products for autoimmune and antibody-mediated diseases. He joined La Jolla Pharmaceutical Company in 1993, advanced to the position of president and member of the board of directors in 1994, CEO in 1995, and chairman of the board in 1997. Prior to joining La Jolla, he held executive-level positions at Cygnus Therapeutic Systems, a developer of drug delivery systems, and Micro Power Systems, Inc., a manufacturer of high technology products, including medical devices. He began his professional career with the Strategic Decisions Group and the Stanford Research Institute. Mr. Engle is a former chairman and current director of BIOCOM, a regional trade association for the biotechnology and medical device industries in Southern California. He served on the board of the Lupus Foundation of America and the San Diego Regional Economic Development Council. Mr. Engle is a graduate of the University of Texas with B.S. and M.S. degrees in biomedical engineering.
William K. Bowes Jr.
Mr. Bowes has been a director since February of 1986 and has been a general partner of U.S. Venture Partners since 1981 and currently holds the position of founding partner. Mr. Bowes is also a director of one private company. He is also a member of the audit committee.
Charles J. Fisher M.D.
Charles J. Fisher, M.D. was elected director in 2007. He is chief medical officer and executive vice president of clinical and regulatory affairs at Cardiome Pharma Corp. He has more than 20 years of leadership experience in clinical research and drug development and, during his earlier academic career, served as principal investigator of numerous clinical trials. Prior to Cardiome Pharma Corp., Dr. Fisher was divisional vice president of global pharmaceutical development at Abbott Laboratories Limited, responsible for the global development of pharmaceuticals, biologics and drug coated medical devices. Prior to Abbott Laboratories Limited, he was an executive director and clinical research fellow at Eli Lilly & Co, where he led the scientific team in the development and regulatory approval of Xigris® (drotrecogin alfa (activated)) for the treatment of severe sepsis. Dr. Fisher also held professor and director positions at numerous academic institutions before joining industry, including the University of Manitoba, the University of California at Davis Medical Center, Case Western Reserve University and the Cleveland Clinic Foundation where he was professor and head of critical care medicine.
Peter Barton Hutt
Mr. Hutt, former chief counsel for the Food and Drug Administration (FDA), became a director in May of 2005. Mr. Hutt is currently senior counsel to the Washington, D.C. law firm of Covington & Burling, specializing in food and drug law and trade association law. Since 1994, he has taught a course on food and drug law at Harvard Law School and taught the same course at Stanford Law School in 1998. He is also a co-author of Food and Drug Law: Cases and Materials. Mr. Hutt serves on a wide variety of academic and advisory boards, including the Institute of Medicine (IOM) of the National Academy of Sciences (NAS) and the Panel on the Administrative Restructuring of the National Institutes of Health (NIH). Additionally, he serves as legal counsel to the Society of Risk Analysis as well as the American College of Toxicology. Formerly, he has served on the IOM Executive Committee, advisory committee to the director of the NIH, the NAS Committee on Research Training in the Biomedical and Behavioral Sciences, and the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS established by the President's Cancer Panel of the National Cancer Institute at the request of President George Bush. Mr. Hutt received his undergraduate degree from Yale University, and law degrees from Harvard University and New York University.
Patrick J. Scannon M.D., Ph.D.
Dr. Scannon is one of the founders of the company and has served as a director since its formation. Dr. Scannon became chief scientific and medical officer in March of 1993. He served as president of the company from its formation until April of 1992 and as vice chairman, scientific and medical affairs from April of 1992 to March of 1993. From 1979 until 1981, Dr. Scannon was a clinical research scientist at the Letterman Army Institute of Research in San Francisco. A Board-certified internist, Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley, and an M.D. from the Medical College of Georgia.
W. Denman Van Ness
Mr. Van Ness serves as the Lead Independent Director and has been a director since October of 1981. He is Chairman of Hidden Hill Advisors, a venture capital consulting firm. From April of 1996 through October of 1999, he was a Managing Director of CIBC Capital Partners, an international merchant banking organization. From 1986 through March 31, 1996, Mr. Van Ness was a General Partner of Olympic Venture Partners II and Rainier Venture Partners, venture capital funds, and from 1977 until 1985, he was a General Partner of the venture capital group at Hambrecht & Quist, the manager of several venture capital funds.
Patrick J. Zenner
Mr. Zenner has been a director since May of 2002. Mr. Zenner is a 32-year veteran of the pharmaceutical industry and spent his entire career at Hoffmann-La Roche. During his first 12 years, he held positions of increasing responsibility in sales, marketing, health care economics, public policy and governmental affairs. In 1982, he became vice president and general manager of Roche Laboratories, and subsequently director and head of global pharma marketing, project development and regulation in Basel, Switzerland. In 1988, he became senior vice president, pharmaceuticals division and a member of the board of directors. From 1993 until his retirement in 2001, he served as president and chief executive officer of Hoffman-La Roche, Inc., North America. Mr. Zenner currently serves on the Boards of Arqule, Inc., Curagen Corporation, Dendrite International, Inc., Exact Sciences Corporation, Geron Corporation, Praecis Pharmaceuticals, Inc., Sciele Pharma, Inc. and West Pharmaceutical Services. He has also served as a member of the board and the executive committee of both the Pharmaceutical Research and Manufacturers Association (PhRMA) and the Biotechnology Industry Organization (BIO).
